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E-mail address: tomi.makela@helsinki.ﬁ (T.P. MäkThe LKB1 tumor suppressor gene is frequently mutated in sporadic lung adenocarcinomas and cer-
vical cancers and germline mutations are causative for Peutz-Jeghers syndrome characterized by
gastrointestinal polyposis. The intracellular LKB1 kinase is implicated in regulating polarity, metab-
olism, cell differentiation, and proliferation – all functions potentially contributing to tumor sup-
pression. LKB1 acts as an activating kinase of at least 14 kinases mediating LKB1 functions in a
complex signaling network with partial overlaps. Regulation of the LKB1 signaling network is highly
context dependent, and spatially organized in various cellular compartments. Also the mechanisms
by which LKB1 activity suppresses tumorigenesis is context dependent, where recent observations
are providing hints on the molecular mechanisms involved.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Genetic evidence linking LKB1 to tumor suppression
Searches for the causative mutations of Peutz-Jeghers syndrome
(PJS) identiﬁed the serine threonine kinase LKB1 as the culprit in
1998 [1,2]. The most prominent symptom associated with PJS is
gastrointestinal polyposis, typically manifesting during the second
or third decade of life and is diagnosed by abdominal pain, bleed-
ing or endoscopy/colonoscopy. The earliest symptom often is
mucocutaneous pigmentation around the lips, oral mucosa, face,
genitalia or palmar surfaces [3]. Benign polyps arise throughout
the gastrointestinal tract, and are pedunculated in shape and clas-
siﬁed as hamartomas [3]. Although hamartomas are expected to
represent most of the differentiated cell types found in the adja-
cent normal tissue, recent studies suggest that the PJS polyps dis-
play differentiation defects both in the epithelial and stromal
components with an increase in myoﬁbroblasts [4,5]. Current
treatment of PJS patients is regular screening for polyps and surgi-
cal interventions as a response to an acute occlusion but also to
prevent gastrointestinal tract occlusions [6].
Currently it appears likely that a germline mutations of LKB1
underlies all properly diagnosed PJS as different approaches have
identiﬁed LKB1 mutations almost in all PJS-patients [6]. The causal
relationship is independently demonstrated by the remarkably
similar polyposis in mice carrying germline inactivating Lkb1
mutations [6]. Interestingly, apparently identical polyps also occurchemical Societies. Published by E
elä).in mice where Lkb1 is inactivated only in stromal SM22-expressing
cells of the smooth muscle lineage implicating the prominent
smooth muscle component in PJS polyps as an important driver
of polyposis [4].
Epidemiological studies have implicated 41–60% overall risk for
PJS patients of developing ﬁrst cancer at the age of 60, whereas
general population risk at this age is 8.5% [7,8]. Accordingly, Lkb1
heterozygote mice in addition to the fully penetrant polyposis
occasionally develop liver carcinomas [9], endometrial cancer
[10] and osteogenic tumors [11]. LKB1 mutations have also been
identiﬁed in sporadic tumors, but in contrast to the enrichment
of gastrointestinal cancers in PJS patients [7], sporadic mutations
have been commonly identiﬁed from non-small cell lung carcino-
mas (NSCLC) [12,13–15] and cancers of the uterine cervix [16]. In
NSCLC mutations are more frequent in adenocarcinomas
[13,14,17]. Biallelic inactivation of LKB1 has been indicated in cer-
vical cancers, whereas one wild type allele is retained in lung ade-
nocarcinomas (see below) [12,13,16]. As several cancer mutation
identiﬁcation methods have relied on loss of heterozygosity
(LOH) it is plausible that current cancer genome sequencing efforts
will identify new tumor types with LKB1 mutations. However, can-
cer genome screens so far have not identiﬁed signiﬁcant amounts
of LKB1 mutations in tumor types studied [17,18].
There is considerable variability (0–34%) in reported LKB1
mutation frequencies in lung adenocarcinomas [12–15,17–20],
probably partly due to methodology, but also likely reﬂecting dif-
ferences in environmental variables and genetic background of
studied patients. Indeed, LKB1 mutations are common in tumorslsevier B.V. All rights reserved.
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smokers [19]. Inactivating LKB1 and activating EGFR mutations
are largely mutually exclusive [14,20], and EGFR mutations in turn
are common in the Asian population [12]. The exclusivity can be
due to (i) EGFR activating and LKB1 inactivating a common can-
cer-promoting pathway, (ii) increased sensitivity of cells carrying
LKB1 mutations to oncogenic stress by EGFR or (iii) EGFR tumors
and LKB1 tumors represent separate subtypes of lung adenocarci-
nomas with differing ‘‘addictions’’ for mutations. p53 (TP53) and
KRASmutations overlap with LKB1mutations [13,20] and the over-
lap between LKB1 and KRAS in one study indicates cosegregation
[14]. In a mouse lung cancer model driven by KRASmutations inac-
tivation of Lkb1 increased tumorigenicity more than p53 mutations
consistent with the notion that LKB1 and KRAS cooperate in lung
tumorigenesis [13].
In cancers of the uterine cervix the only recurrent mutation
identiﬁed is in LKB1, identiﬁed in up to 20% of cervical cancers,
including the tumor used to generate the HeLa cell line [16]. This
warrants a closer look at the potential cooperation between LKB1
and the known factors promoting cervical cancer including the
E6 and E7 oncogenes of the Human papilloma virus (HPV)-genome
present in almost all cervical cancers. HPV E6 and E7 inactivate p53
and retinoblastoma (pRB) functions [21], and a further promoter of
cervical cancer is estrogen expression [22]. Here studies on Lkb1
inactivation in E6 and E7 expressing mouse models of cervical can-
cer [22] might reveal more detailed mechanisms on how LKB1
activity intersects with these pathways. The cooperation between
estrogen and LKB1 is supported by studies in endometrial cancer,
where an inverse correlation between LKB1 staining and endome-
trial cancer grade was noted in human tumors [10], and where
Lkb1 mutations promote tumors in mice [10,23].
2. Haploinsufﬁciency and biallelic inactivation of LKB1
A meta-analysis of reported LKB1 mutations [24–27] in Peutz-
Jeghers Syndrome indicates that 60% (n = 92) of polyps retain a
wild type allele, suggesting that biallelic inactivation as detected
by loss of heterozygosity is not a required event for tumorigenesis.
Mice carrying germline inactivating mutations of Lkb1 phenocopy
PJS polyposis with full penetrance [6] and thus allow for a robust
platform to analyze this and other molecular changes leading to
polyposis. Biallelic inactivation was either not detected [28] or only
noted in part of the tumors [29]. These results suggest that Lkb1 is
haploinsufﬁcient in suppressing PJS tumor initiation consistently
with its behavior in regulating signaling in cell culture [4,30]. At
the same time the occasional identiﬁcation of biallelic inactiva-
tions in both human and mouse polyps indicates that a ‘‘second
hit’’ may provide a further growth advantage as noted in one study
[4] and warrants further investigation.
Biallelic inactivation of LKB1 as detected by LOH was not com-
monly identiﬁed in recent analyses of NSCLC [12,13]. Also the lung
adenocarcinomas in KRAS;Lkb1+/ mice retain expression of wild
type Lkb1 [13]. LKB1 mutations may be early events in NSCLC as
mutation frequency does not correlate with clinical stage [14].
These observations suggest that carriers of germline LKB1 muta-
tions should be at high risk of NSCLC which has not been noted
in PJS patients [7]. Possible explanations might be altered smoking
behavior or decreased life expectancy of PJS patients. It is also pos-
sible that LKB1 heterozygosity at a very early point in tumorigene-
sis is disadvantageous e.g. due to oncogenic stress where LKB1
mutations in sporadic lung adenocarcinomas would take place
only after genetic changes conferring resistance to oncogenic
stress.
In KRAS-induced lung cancer in mice Lkb1 inactivation increased
not only tumor number but also tumor burden and metastases [13]and resistance to PI3K-mTOR and MEK pathway inhibition [31].
These phenotypes beneﬁted from biallelic deletion [13] consistent
with the notion that a ‘‘second hit’’ provides a further advantage
for tumor progression. This would predict a higher frequency of
LOH or epigenetic silencing of wild type LKB1 allele in metastasis
compared to primary tumors. Also the noted loss of LKB1 expres-
sion in some lung adenocarcinomas [12,15,32] should correlate
with worse disease outcome.
In contrast to NSCLC, LKB1 mutations in cervical cancer repre-
sent biallelic inactivations. Interestingly, they also associate with
poor prognosis [16]. The much less frequently noted LKB1 muta-
tions in other tumor types have mostly been biallelic e.g. in liver,
colorectal, breast, pancreas and sex cord tumors [6]. Accordingly,
in Lkb1 heterozygote mice LOH was found in the more rare tumors
of the liver [9], endometrium [10] and in carcinogen-induced skin
cancer [33]. LKB1 LOH has also been detected in 76% (n = 29) of PJS-
patient carcinomas [24–27]. Thus biallelic inactivation of LKB1 is
more common in cancers than in PJS polyps again supporting the
notion that biallelic inactivation promotes progression.
3. LKB1 kinase complex and its regulatory mechanisms
LKB1 encodes a serine threonine kinase of 433 amino acids,
which is active in a complex with a pseudokinase STRAD (STRADa
or STRADb) and scaffold MO25 (MO25a or MO25b) [34,35]. Both
kinase domain integrity [34] and in one case the ability to bind
STRAD [36] appears to be crucial for LKB1-mediated tumor sup-
pression. Mutations of STRAD or MO25 genes have not been found
in PJS patients [6] or adenocarcinomas of the lung [20], which may
be due to redundancy or alternatively suggests LKB1 may act with-
out STRAD and/or MO25 as recently identiﬁed for PAR-4, the Cae-
norhabditis elegans ortholog of LKB1 [37].
Early studies identiﬁed several substrates of LKB1 including p53
[38,39], PTEN [40], and LIP1 [41]. Attention was redirected with the
identiﬁcation of LKB1 as the activating kinase of the catalytic sub-
unit of the AMP-activated protein kinase (AMPK) [42] as well as
several other kinases with a T-loop activation domain similar to
AMPK [43]. Together these form the identiﬁed 14 LKB1 substrate
kinases: AMPKa1-2, BRSK1-2 (also known as SAD-B and SAD-A),
MARK1-4, NUAK 1-2, SIK1-3 (SIK1, QIK and QSK, respectively)
and SNRK [34]. The LKB1 kinase complex has been demonstrated
to be required for the activation of these kinases in cell culture
[42,43] and for several of them also in vivo [10,13,32,33,44–46].
Alternative activation mechanisms for the substrate kinases have
only been identiﬁed for AMPKa1, which is phosphorylated and
activated in heart and skeletal muscle in the absence of Lkb1 prob-
ably by CamKK [34].
Regulation of LKB1 and the phosphorylation of the T-loop acti-
vation site of various LKB1 substrate kinases is highly cell type and
context speciﬁc. In melanoma cells activated RAF signaling induces
ERK and RSK to phosphorylate S325 and S428, respectively, which
was suggested to compromise the ability of LKB1 to bind and acti-
vate AMPK [47]. In neurons, BDNF-induced activation of PKA in a
single neurite outgrowth triggers localized phosphorylation of
S428 (S431 in mice), which in this setting appears to stabilize
the LKB1–STRAD–MO25 complex required for axon speciﬁcation
[44,48]. During immunoglobulin gene remodeling DNA strand
breaks induce ATM, which in this context leads to phosphorylation
of LKB1, inactivation of CRTC2 (also known as TORC2) and differen-
tiation of B cells [49], which suggests a mechanism where ATM
phosphorylation of LKB1 on T366 [50], induces LKB1 to phosphor-
ylate either SIK or AMPK, both capable of phosphorylating and
inactivating CRTC2 [51]. In myocytes and adipocytes Fyn-mediated
tyrosine phosphorylation on Y261 and Y365 of LKB1 decreases
cytoplasmic LKB1 and AMPK T-loop phosphorylation [52].
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where in each it appears to mediate speciﬁc functions. The C-ter-
minus of LKB1 contains a conserved prenylation site required for
membrane localization and establishment of polarity in Drosophila
oocytes [53] and for localization to adherence junctions in MDCK
cells [54]. LKB1 in the primary cilium is implicated in cell size reg-
ulation through AMPK [55]. LKB1 has a functional nuclear localiza-
tion signal [56,57] and chromatin-bound LKB1 has been implicated
in activating AMPK leading to H2B-S36 phosphorylation and acti-
vation of p21 transcription in response to glucose deprivation
(Fig. 1) [58]. On the other hand, LKB1 lacking the NLS retains the
ability to restrict growth of LKB1-deﬁcient cells, and STRAD and
MO25 association enriches cytoplasmic LKB1 [36,59].
A further level of regulation is conformation of substrates. It has
been proposed that T-loop phosphorylation of 10 out of 14 LKB1
substrates is enhanced by an intramolecular interaction between
the kinase domain and a ubiquitin-associated (UBA) domain,
where ubiquitinylation prevents this interaction [60,61]. The
AMPK kinase complex contains regulatory AMPKb and AMPKc sub-
units. A myristoyl-switch of AMPKb and AMP binding to AMPKc
have been suggested to stimulate LKB1-mediated T-loop phos-
phorylation of AMPKa [62], whereas other studies suggest that
AMP binding to AMPKc induces a conformational change in AMP-
Kamaking it a worse substrate for the phosphatase [63,64]. Spatial
and temporal regulation of phosphatase activity is likely to be rel-
evant for other LKB1 substrate kinases as well.
4. LKB1 and AMPK in control of proliferation and metabolism
LKB1 signaling has been implicated in promotion of prolifera-
tive senescence in a p53-independent manner [29,65] and of cellFig. 1. Signaling by LKB1 substrate kinases potentially involved in tumor suppression. In
kinases in several cellular compartments. Decreased energy levels lead to increased AMP
in turn inhibits ATP-consuming anabolic reactions such as fatty acid synthesis (2) and pro
whereas MARK kinases phosphorylate microtubule associated proteins (MAPs) thus decre
for centrosome duplication and separation, respectively. NUAK kinases are involved in inh
of the phosphatase complex (with PP1 and MYPT1 subunits shown) by 14-3-3 subseque
phosphatase on actin ﬁbers in partially kinase independent manner. In primary stroma
mediated through NUAK and actin ﬁbers (dashed arrow). In the nucleus LKB1 has bee
transcription via AMPK and SIK1; both phosphorylation of p53 and histone 2B (H2B) have
functions have not been characterized (8). For references, please see text.cycle arrest and cell death in p53-dependent manner [39,57,66–
68]. p53-dependent regulation of cell number by LKB1 might be
mediated by direct phosphorylation of p53 S15 by LKB1 substrate
kinases AMPK and SIK1 in response to glucose starvation [67] or
cell detachment (Fig. 1) [66]. p53 S15 phosphorylation induces
p21 [69] and consistently LKB1-mediated cell cycle arrest of
LKB1-deﬁcient cells is p53-dependent and induces p21 levels
[57]. These effects were mediated also by an LKB1 lacking the nu-
clear localization signal [57] suggesting that LKB1 was not involved
in direct p53 S15 phosphorylation [39].
In considering the relevance of p53 and possibly S15 phosphor-
ylation in LKB1 mediated tumor suppression an interesting com-
parison is offered by the ATM kinase strongly implicated in S15
phosphorylation. The observation that p53 and ATM mutations
are mutually exclusive in lung adenocarcinomas and mutation of
either p53 or ATM leads to increased mutation rates [20] suggests
that p53 is critical for ATM tumor suppression. By contrast, LKB1
and p53 mutations are concurrent in lung adenocarcinomas
[13,15,20] and LKB1 mutations are not associated with increased
mutations rates [20]. Also the tumor spectrum of Lkb1 deﬁciency
and p53 deﬁciency in mice do not overlap, but p53 mutations en-
hance polyp initiation in Lkb1+/ mice (our unpublished results)
[70,71]. On the other hand, decreased LKB1staining in pancreatic
cancers correlates with decreased p21 staining only in tumors that
did not express mutant p53 [72]. These results suggest that de-
creased signaling from LKB1 to p53 may contribute to early stages
of tumorigenesis, but that p53 loss in lung adenocarcinomas is a la-
ter event allowing increased mutation rates or tolerance to in-
creased mutation burden of tumors.
In line with the ability of AMPK to induce cell cycle arrest, evi-
dence for it playing a part in tumor suppression by LKB1 is emerg-mammalian cells LKB1 kinase complex (1), modiﬁed from [35] activates substrate
which together with LKB1 activate the AMP-activated protein kinase (AMPK), which
tein translation (3). AMPK phosphorylates CLIP-170 increasing microtubule stability,
asing microtubule stability (4). The LKB1 substrates BRSK1 and SIK2 (5) are required
ibition of MLC dephosphorylation (6), which can take place either via sequestration
nt to phosphorylation of MYPT1 by NUAK or via MRIP-dependent inhibition of MLC
l cells LKB1 positively regulates TGFb signaling and production (7), which may be
n identiﬁed in a complex with AMPK and p53 and implicated in p53-dependent
been proposed as mechanisms. The involvement of STRAD and MO25 in these LKB1
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have revealed a signiﬁcant decrease in cancer incidence and mor-
tality among patients treated with the AMPK activator metformin
in comparison to non-treated, insulin or sulfonylurea treated pa-
tients [73,74]. Activation of AMPK with metformin, phenformin
or A-769662 also led to decreased tumor burden in PTEN heterozy-
gote mice, whereas LKB1 hypomorphism and associated deﬁcient
activation of AMPK increased tumor burden of PTEN heterozygote
mice [75]. Subsequent to these reports a wealth of clinical studies
using metformin for treatment of diabetic and non-diabetic pa-
tients have been started (12 ongoing and 1 completed clinical trial
can be found in http://www.clinicaltrials.gov).
Signaling downstream of AMPK is dedicated to improve cellular
energetic state [63], whereas cancer cells are often using all possi-
ble energy to growth. Thus inactivation of AMPK signaling may be
in the interest of cancer cells tilting the balance toward lipid syn-
thesis and maintenance of mTOR activity, which stimulates protein
translation via S6K and 4EBP1 (Fig. 1) [51] and possibly mediates
AMPK-dependent autophagy [76,77].
On the other hand, also cancer cells can run into an energy def-
icit, and this can be exacerbated by the hypoxic environment and/
or shift in energy production frommitochondrial citric acid cycle to
glycolysis, known as the Warburg effect [78]. Consistently there
are also tumor models where AMPK is activated [79,80], and could
represent cells which have been initially glucose-addicted, but
now experiencing low glucose [81] or where autophagy and fatty
acid beta oxidation are otherwise critical [82]. Considering these
variations use of AMPK activating drugs as cure for cancer should
be carefully considered.
Although several lines of correlative evidence support a role for
AMPK in LKB1 tumor suppression direct genetic evidence is scarce.
Decreased AMPK activity has been noted in several LKB1-deﬁcient
mouse models [10,13,33,45]. Also mTOR pathway activation has
been noted in epithelia of polyps in Lkb1+/ mice [83] suggested
to be due to reduced AMPK activity. However, mTOR pathway
was also activated in polyp epithelia without Lkb1 mutations [4]
indicating it is not linked with Lkb1 mutations, and indeed mTOR
pathway activation is very common in human tumors. Therefore
attenuation of polyp growth with the mTOR inhibitor rapamycin
[84,85] does not directly link AMPK to LKB1 tumor suppression
in this model. In another study using the KRAS induced lung ade-
nocarcinoma model the increased metastatic capacity of tumors
with Lkb1 mutations was suggested to be mediated through in-
creased expression of lysyl oxidase (LOX) due to increased mTOR
and HIF1a [86]. The apparent discrepancy between LKB1mutations
(not correlated with clinical stage but correlated with smoking)
[14] and LOX expression (correlated with clinical stage and meta-
static status in human tumors but not with sex or smoking) [86]
indicate further studies are needed to have direct evidence for a
role for AMPK also in lung adenocarcinoma. Melanomas carrying
BRAFV600Emutations have also been suggested to inactivate AMPK
through LKB1 phosphorylation [47] as discussed above. The rele-
vance for this pathway in melanoma is important to investigate
further including analysis of how LKB1 phosphorylation affects
LKB1 activity toward other substrates as well as how exogenous
LKB1 arrests G361 melanoma cells carrying the V600E mutation
(Cosmic database and) [36,57,87].
The lack of AMPKa1 and a2 mutations in PJS patients, sporadic
lung adenocarcinomas, or other tumor types suggest that either
AMPKa1 or a2 are not sole mediators of tumor suppression by
LKB1 in these tissues or alternatively that AMPKa1 or a2 are redun-
dant in potential tumor suppressive function. Analysis of AMPKa1/
;a2/ mice indicate redundancy at least during embryogenesis
[88]. However, the differential expression pattern of AMPKa1 and
AMPKa2 alleles in e.g. gastrointestinal tissues (our unpublished
data and) [89] and the haploinsufﬁciency of LKB1 in polyp initia-tion (see Section 2) indicate it will be interesting to investigate
whether AMPKa1/ and AMPKa2/ mice or tissue-speciﬁc double
knockouts are susceptible to tumorigenesis.5. LKB1 in regulating TGFb-dependent cell differentiation
Peutz-Jeghers polyps contain a characteristic prominent smooth
muscle core. The observation that polyp epithelial cells do not
commonly carry secondary LKB1 mutations (see above) indicated
that it was not clear which cell types were important for polyp for-
mation in carriers of germline LKB1 mutations. Interestingly,
smooth muscle speciﬁc deletion of Lkb1 induces polyps with a
prominent smooth muscle core and hyperproliferative epithelia
[4] indicating the smooth muscle Lkb1 has a non-cell-autonomous
role in controlling epithelial proliferation. Lkb1 loss in stromal cells
was associated with decreased TGFb signaling and TGFb produc-
tion (Fig. 1) and lead to differentiation defects of the SMC-lineage
[4,30]. Decreased TGFb signaling to epithelial cells [4] may repre-
sent the mechanism allowing epithelial hyperproliferation and dif-
ferentiation defects [5]. The polyps driven by stromal Lkb1 deletion
were indistinguishable from polyps in Lkb1+/ mice and PJS pa-
tients including the TGFb signaling defects providing evidence that
smooth muscle LKB1 mutations are also critical in PJS polyposis.
This is also supported by apparent lack of similar tumors upon epi-
thelial Lkb1 deletion [46,90]. Thus Lkb1 can be considered a land-
scaper tumor suppressor [91] for PJS polyposis. Landscaper tumor
suppression has been previously identiﬁed in mice with deletion
of TGFbRII in ﬁbroblasts leading to prostate and stomach carcinoma
[92], and in mice with deletion of Smad4 in T cells leading to epi-
thelial tumors [93] with similarities with Juvenile Polyposis (JP)
syndrome harboring SMAD4 mutations.
In myoﬁbroblasts LKB1 regulates TGFb signaling between
receptor activation and target gene activation [30]. Interestingly,
the LKB1 substrate kinase NUAK2 has been reported to interact
with TGFbRI, Smad2 and Smad4 suggesting that NUAK2 regulates
recruitment or full activation of Smad’s (Fig. 1) [94,95]. Alterna-
tively, LKB1 substrate kinase phosphorylation and activation of
p53 could be needed for proper activation of Smad dependent tran-
scription [96].
The mode of LKB1 mediated regulation on TGFb signaling is
possibly cell/tissue speciﬁc as, similarly to stromal cells, LKB1 is
critical for TGFb signaling in endothelial cells in vivo [97], whereas
attenuated LKB1 signaling was associated with enhanced TGFb sig-
naling in multiple epithelial cell lines [31,98]. Interestingly, down-
regulation of LKB1 in epithelial cell lines has been implicated in
induction of epithelial to mesenchymal transition (EMT)
[31,98,99], which could explain the increased metastasis of Lkb1
mutated lung adenocarcinomas [13,31]. Possible mechanisms of
TGFb signaling suppression by LKB1 include the downregulation
TGFbRI ALK5 by LKB1 substrate SIK1 [100] and inhibition of Smad4
when in a complex containing LKB1, LIP1 and Smad4 [41,98].
Whether the increased TGFb signaling noted in some experimental
systems is at play in gastrointestinal epithelial and whether it con-
tributes to epithelial differentiation defects observed in Lkb1 mu-
tated mice [5,46] and PJS patients [5] requires further
investigation.6. LKB1 regulates cell polarity by controlling microtubule and
actin dynamics
LKB1 and its orthologues have critical roles in regulation of cell
polarity in several model systems. PAR-4, a C. elegans orthologue of
LKB1, was identiﬁed as one of the six partitioning defective genes
regulating asynchronous and asymmetric cell division of an early
embryo [101], whereas drosophila LKB1 has been shown to regu-
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indicated conservation of polarity regulation by LKB1 in mamma-
lian cells (see below). Many changes resulting from defects in
polarity including mitotic spindle defects, defective tissue integ-
rity, epithelial to mesenchymal transition and subsequently in-
creased cell motility are associated with cancer initiation and
progression [102], and therefore it is important to consider these
as a potential mechanism of LKB1 mediated tumor suppression.
Loss of asymmetric cell divisions are in part caused by deﬁcient
microtubule dynamics and deﬁcient orientation of mitotic spindle.
In C. elegans PAR-4 controls spindle pole positioning via activation
of MARK kinase orthologue PAR-1 [101,103]. MARK kinases in-
crease microtubule dynamics via phosphorylation of microtubule
associated proteins (Fig. 1) [104] and MARK4 associates with
microtubules and centrosomes [105]. In Drosophila melanogaster
LKB1 is critical for mitotic spindle formation and morphology in
larval brains [106] and S2 cells [107]. These effects could be med-
iated by SIK3 homologue CG15072 whose silencing mimics the
LKB1 phenotype in S2 cells [107]. In mammalian cells LKB1 sub-
strate kinases BRSK1 and SIK2 have been reported to localize to
centrosomes where BRSK1 mediated phosphorylation on Ser-131
of gamma-tubulin [108] and SIK2 mediated phosphorylation on
Ser-2392 of centrosomal linker protein C-Nap1 [109] are required
for centrosome duplication and centrosome separation during
mitosis, respectively (Fig. 1).
Thus LKB1 is implicated in regulation of several aspects of mito-
tic spindle formation and orientation. Deregulation of these pro-
cesses often takes place in human cancer resulting in polyploidy
and misorientation of the plane of division of epithelial cells. Stud-
ies on lung adenocarcinoma samples should reveal whether LKB1
mutated tumors demonstrate more severe mitotic spindle defects
than LKB1 wild type tumors or whether mutations of LKB1 and
other driver genes indicated in regulation of mitotic spindle are
mutually exclusive.
Normal tight and adherence junctions promote epithelial polar-
ity and prevent epithelial mesenchymal transition, which is associ-
ated with cancer progression. In MDCK cells downregulation of
LKB1 and subsequent decrease in AMPK activation has been impli-
cated in deﬁcient formation of tight junctions upon calcium switch
[110,111] and in bile canalicular network model LKB1–AMPK sig-
naling activity is critical for polarity formation and maintenance
[112]. LKB1 has been suggested to regulate also adherence junc-
tions as LKB1 nullizygosity leads to disorganized adherence junc-
tions in Drosophila eye rhabdomeres [113] and LKB1 associates
with adherence junctions in MDCK cells [54]. Furthermore, LKB1
deletion in developing mouse pancreas with Pdx1-Cre leads to dis-
ruption of adherence and tight junctions and is correlated with cyst
formation by acinar cells [45]. Here Lkb1 might be essential for
cell–cell junction formation during development of the pancreas
as defects in these have not been reported upon LKB1 deletion in
the mature pancreas where, instead, deﬁcient positioning of the
nucleus and primary cilia were observed in response to Lkb1 or
Mark2 deletion [114,115]. Cell–cell junction formation is essential
for polarization and lumen formation of mammary epithelial struc-
ture. Indeed, polarization and lumen formation by MCF10A breast
cancer cells is attenuated in a 3D model upon LKB1 knockdown
[116] and, accordingly, Lkb1 deletion in mouse mammary glands
lead to development of ductal carcinomas [117]. Although LKB1
mutations in sporadic breast cancers are rare [118], carriers of
germline LKB1 mutations have increased breast cancer incidence
[7], which suggest a potential role for regulation of epithelial integ-
rity in LKB1 tumor suppression.
Establishment andmaintenance of cell–cell junctions are depen-
dent on actin cytoskeleton and thus cell junction defects upon
deregulation of LKB1might reﬂect problems in actin dynamics. Here
LKB1 is suggested to be required for myosin regulatory light chain(MLC/MRLC)phosphorylation onThr18–Ser19 [119,120]. Phosphor-
ylated MLC increases actomyosin contraction and actin stress ﬁber
formation via activation ofmyosin, which triggers positive feedback
loop between contraction and MLC phosphorylation [121]. Overex-
pression of a phospho-mimetic of Thr18 and Ser19 MLC rescues
polarity and polyploidy defects of epithelial cells in LKB1 and AMPK
mutant ﬂies [122] and mimics LKB1 kinase complex dependent
polarization of a single colorectal cancer cells [122,123]. Whether
MLC is the direct target of AMPK remains still controversial
[122,124]. On the other hand, NUAK1 and NUAK2 have been sug-
gested to positively regulate MLC phosphorylation via inhibition of
MLC-phosphatase complex.NUAK1 interactswithPP1 catalytic sub-
unit and phosphorylates three sites on the regulatory subunit
MYPT1 (PP1RC12A) to create 14-3-3 binding epitopes leading to
sequestration of the phosphatase complex [125], whereas PP1 inhi-
bition by NUAK2 is suggested to take place on actin stress ﬁbers in
MRIP dependent and partially kinase independent manner [120].
Here binding of phosphatase complex and NUAK2 on MRIP leads
to inhibition of the phosphatase, which together with upregulation
of NUAK2 levels in conditions of prominent stress ﬁbers depicts a
positive feedback loop resulting in increased stress ﬁbers (Fig. 1)
[120]. Accordingly, deletion of Lkb1 in primary MEFs has been indi-
cated in loss of actin stress ﬁbers [30]. Thus it is plausible that
NUAK1, NUAK2 and AMPKmediate LKB1 function in actin cytoskel-
eton regulation in a context dependent manner.
Deﬁcient cell–cell junctions and altered actin and microtubule
dynamics are associated with increased cell motility and cancer
cell metastasis [126]. Indeed, LKB1 mutations are correlated with
aggressive phenotype of tumors [14,16] and cause increased inva-
siveness in mouse cancer models [13,23]. Both, microtubule desta-
bilization by BRSK1-2 or MARK1-4 mediated phosphorylation on
microtubule associated proteins [44,104] and reported increase
in microtubule stability and polymerization upon AMPK mediated
phosphorylation on microtubule + end motor CLP-170 [127] have
been associated in regulation of cell migration. In a separate study
overexpression of LKB1 mutants found in tumors interfered with
microtubule polarization during astrocyte migration [128]. Also in-
creased phosphorylation of MLC, which is controlled in part by
NUAK kinases [120,125], and subsequently enhanced cell contrac-
tility has been shown to be critical determinant of cell migration.
Actin and focal adhesions dynamics are reciprocally regulated
and interestingly focal adhesion kinase activation has been associ-
ated with LKB1 inactivation in cell culture and in vivo [31]. The po-
tential role of multiple LKB1 substrate kinases in regulation of cell
motility calls for careful analysis of LKB1 substrate activation in
space and time in motile cells to distinguish their roles.7. Concluding remarks
Identiﬁcation of frequent LKB1 mutations in adenocarcinomas
of the lung [20] and cervical cancer [16] has promoted LKB1 as
one of the central tumor suppressors. Because of apparent lack of
LOH of LKB1 loci at least in some tumor types [4,13,28], LKB1muta-
tions might have been missed in earlier studies as LOH has been
considered as criteria of tumor suppressor. Thus cancer genome
and epigenetic screening approaches might reveal new tumor
types carrying LKB1 mutations. Accordingly, tumor sample screen-
ing for decreased LKB1 levels by immunohistochemistry has been
used for identiﬁcation of LKB1 deﬁcient cancer types [10]. How-
ever, the lack of a well-established and controlled reagent for
immunohistological staining of LKB1 has hampered wide-spread
use of this useful approach. Thus efforts in production of better
antibodies and perhaps even LKB1 activity assays will beneﬁt stud-
ies on LKB1 deﬁciencies in variety of tumors and metastasis and
will clarify in which cell types LKB1 levels are decreased in tumors.
K. Vaahtomeri, T.P. Mäkelä / FEBS Letters 585 (2011) 944–951 949It is not clear which LKB1 signaling pathways are involved in tu-
mor suppression. Combining existing tumor models with overex-
pression of activated mutant or deletion of LKB1 substrate
kinases could reveal the relevant LKB1 downstream targets inhib-
iting initiation and metastasis of tumorigenic cells in vivo. Also
studies on Lkb1 phosphorylation site mutant knock-in mice are
likely to clarify the role of different upstream regulators in LKB1
tumor suppression. Studies on LKB1 will beneﬁt cancer research
but will also shed light on basic principles of metabolism and tis-
sue integrity.
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